The rapid progression of KRAS(G12C) inhibitors from preclinical characterization to the clinic has radically changed the perception of the KRAS oncogene as an undruggable target. Here we discuss ongoing and future possibilities for developing therapies using these inhibitors in clinical settings.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Case report: single-cell transcriptome sequencing reveals the clonal origin of mature plasmacytoid dendritic cell proliferation in early T-cell precursor lymphoblastic leukemia
Annals of Hematology Open Access 14 March 2025
-
KRAS-mutant non-small cell lung cancer (NSCLC) therapy based on tepotinib and omeprazole combination
Cell Communication and Signaling Open Access 12 June 2024
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to the full article PDF.
USD 39.95
Prices may be subject to local taxes which are calculated during checkout
Change history
04 April 2022
A Correction to this paper has been published: https://doi.org/10.1038/s43018-022-00372-3
References
Kim, D., Xue, J. Y. & Lito, P. Cell 183, 850–859 (2020).
Li, C. et al. Science 374, https://doi.org/10.1126/science.abf1730 (2021).
Lou, K. et al. Sci. Signal. 12, eaaw9450 (2019).
Manchado, E. et al. Nature 534, 647–651 (2016).
Koga, T. et al. J. Thorac. Oncol. 16, 1321–1332 (2021).
Xue, J. Y. et al. Nature 577, 421–425 (2020).
Kruspig, B. et al. Sci. Transl. Med. 10, eaao2565 (2018).
Hong, D. S. et al. N. Engl. J. Med. 383, 1207–1217 (2020).
Skoulidis, F. et al. N. Engl. J. Med. 384, 2371–2381 (2021).
US Food and Drug Administration. https://www.fda.gov/news-events/press-announcements/fda-approves-first-targeted-therapy-lung-cancer-mutation-previously-considered-resistant-drug (2021).
Awad, M. M. et al. N. Engl. J. Med 384, 2382–393 (2021).
Tulpule, A. et al. Cell 184, 2649–2664.e2618 (2021).
Acknowledgements
R.R. reports funding from the Spanish Association Against Cancer (AECC; grant PROYE18012ROSE), a European Union Horizon 2020 research and innovation program, Marie Sklodowska-Curie grant agreement ELBA N 765492 and the Talent-UAB grant to support recruitment and retention of research talent at the Autonomous University of Barcelona.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Rosell, R., Aguilar, A., Pedraz, C. et al. KRAS inhibitors, approved. Nat Cancer 2, 1254–1256 (2021). https://doi.org/10.1038/s43018-021-00289-3
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s43018-021-00289-3
This article is cited by
-
Case report: single-cell transcriptome sequencing reveals the clonal origin of mature plasmacytoid dendritic cell proliferation in early T-cell precursor lymphoblastic leukemia
Annals of Hematology (2025)
-
KRAS-mutant non-small cell lung cancer (NSCLC) therapy based on tepotinib and omeprazole combination
Cell Communication and Signaling (2024)
-
It’s a wrap for 2021!
Nature Cancer (2021)
